类风湿关节炎患者接受髋部骨折、腹盆腔及心脏手术时免疫抑制与再入院和死亡风险
结果显示生物制剂/tsDMARD与甲氨蝶呤相比未增加风险,而较高剂量糖皮质激素与风险增加相关。
要点
- 术前使用TNFi或非TNFi生物制剂/tsDMARD与甲氨蝶呤相比,未增加90天死亡或30天再入院风险。
- 糖皮质激素5-10 mg/天和>10 mg/天与死亡和再入院风险增加相关,但按手术类别分层后结果有差异。
- 该研究提示在非关节置换大手术前,生物制剂/tsDMARD可能无需停用,而糖皮质激素剂量需关注。
核心结论
- 近期使用生物制剂或tsDMARD与甲氨蝶呤相比,未增加髋部骨折、腹盆腔或心脏手术后的死亡或再入院风险。
- 较高剂量糖皮质激素与死亡和再入院风险增加相关。
研究设计与样本
- 回顾性队列研究,使用2006-2015年Medicare数据,纳入接受髋部骨折修复、腹盆腔手术或心脏手术的类风湿关节炎成人患者。
- 采用倾向评分逆概率加权逻辑回归,比较术前8周内使用甲氨蝶呤(未联用生物制剂或tsDMARD)、TNFi或非TNFi生物制剂/tsDMARD患者的90天死亡和30天再入院风险。
主要发现
- 与甲氨蝶呤相比,TNFi组90天死亡aOR 0.83(0.67-1.02),30天再入院aOR 0.86(0.75-0.993)。
- 与非TNFi生物制剂/tsDMARD组相比,死亡aOR 0.78(0.49-1.22),再入院aOR 1.02(0.78-1.33)。
- 按手术类别分层分析结果相似。
- 与未使用糖皮质激素相比,5-10 mg/天组死亡aOR 1.41(1.08-1.82),再入院aOR 1.26(1.05-1.52)。
- >10 mg/天组死亡aOR 1.64(1.02-2.64),再入院aOR 1.60(1.15-2.24),但按手术类别分层后结果有差异。
临床怎么用
- 对于接受髋部骨折、腹盆腔或心脏手术的类风湿关节炎患者,术前使用生物制剂或tsDMARD可能不增加短期死亡或再入院风险。
- 术前应关注糖皮质激素剂量,较高剂量与不良结局风险增加相关。
局限性
- 回顾性观察性研究,可能存在残余混杂。
- 仅使用Medicare数据,结果可能不适用于其他人群。
- 糖皮质激素分析按手术类别分层后结果有差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The impact of immunosuppression on postoperative outcomes has primarily been studied in patients undergoing joint replacement surgery. We aimed to evaluate the impact of biologics and glucocorticoids on outcomes after other major surgeries. METHODS: This retrospective cohort study used Medicare data 2006-2015 to identified adults with rheumatoid arthritis undergoing hip fracture repair, abdominopelvic surgery (cholecystectomy, hysterectomy, hernia, appendectomy, colectomy) or cardiac surgery (coronary artery bypass graft, mitral/aortic valve). Logistic regression with propensity-score-based inverse probability weighting compared 90-day mortality and 30-day readmission in patients receiving methotrexate (without a biologic or targeted synthetic disease-modifying antirheumatic drug (tsDMARD)), a tumour necrosis factor inhibitor (TNFi) or a non-TNFi biologic/tsDMARD <8 weeks before surgery. Similar analyses evaluated associations between glucocorticoids and outcomes. RESULTS: We identified 10 777 eligible surgeries: 3585 hip fracture, 5025 abdominopelvic and 2167 cardiac surgeries. Compared with patients receiving methotrexate, there was no increase in the risk of 90-day mortality or 30-day readmission among patients receiving a TNFi (mortality adjusted OR (aOR) 0.83 (0.67 to 1.02), readmission aOR 0.86 (0.75 to 0.993)) or non-TNFi biologic/tsDMARD (mortality aOR 0.78 (0.49 to 1.22), readmission aOR 1.02 (0.78 to 1.33)). Analyses stratified by surgery category were similar. Risk of mortality and readmission was higher with 5-10 mg/day of glucocorticoids (mortality aOR 1.41 (1.08 to 1.82), readmission aOR 1.26 (1.05 to 1.52)) or >10 mg/day (mortality aOR 1.64 (1.02 to 2.64), readmission aOR 1.60 (1.15 to 2.24)) versus no glucocorticoids, although results varied when stratifying by surgery category. CONCLUSIONS: Recent biologic or tsDMARD use was not associated with a greater risk of mortality or readmission after hip fracture, abdominopelvic or cardiac surgery compared with methotrexate. Higher dose glucocorticoids were associated with greater risk.
引用
- George MD, Baker JF, Winthrop KL, et al. Immunosuppression and the risk of readmission and mortality in patients with rheumatoid arthritis undergoing hip fracture, abdominopelvic and cardiac surgery. Ann Rheum Dis. 2020. PMID: 32209540. doi:10.1136/annrheumdis-2019-216802
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。